(Bloomberg) — Regeneron Pharmaceuticals Inc. climbed the most in more than three months on Monday after U.S. President Donald Trump received the biotech company’s antibody cocktail to treat Covid-19.President Trump’s treatment was the “ultimate validation” for Regeneron, according to SVB Leerink analyst Geoffrey Porges.Like Regeneron, Eli Lilly & Co. and AbCellera Biologics Inc. are developing an antibody therapy, not only as a treatment for the virus but also as a preventative. When used as a prophylactic, these products could be considered a passive vaccine as opposed to the active shots most people think of as a vaccine, Bloomberg Intelligence’s Sam …read more
Source:: Yahoo Finance
